|
|
 |
| Àâòîðèçàöèÿ |
|
|
|
| Ïîèñê ïî óêàçàòåëÿì |
|
|
|
|
|
|
|
 |
|
|
|
| Lanza R. (ed.), Weissman I. (ed.), Thomson J. (ed.) — Handbook of Stem Cells (vol. 1) Embryonic Stem Cells |
|
|
|
| Ïðåäìåòíûé óêàçàòåëü |
Transcriptional regulation, thymus development 2: 556—557
Transcriptional regulation, transcription factor interaction 2: 87—88 2:
Transcriptional regulation, use of gene chips to identify pathways of 1: 581—586
Transdifferentiation 2: 83—84
Transdifferentiation as injury response 2: 477—478
Transdifferentiation by cell reprogramming 2: 148—149 2:
Transdifferentiation by transplantation 2: 148
Transdifferentiation in adult pancreatic cells 2: 515—517
Transdifferentiation of non-islet cells to islet cells 2: 733—734
Transdifferentiation of somatic cells in culture 2: 148
Transdifferentiation, adult stem cell potential 2: 147 2:
Transdifferentiation, aging effects 2: 341—342
Transdifferentiation, biologic significance 2: 139
Transdifferentiation, bone marrow stem cells 2: 475—477 2:
Transdifferentiation, clinical implications 2: 139 2: 2:
Transdifferentiation, dedifferentiation and 2: 142 2:
Transdifferentiation, defined 2: 139 2:
Transdifferentiation, evidence of 2: 155
Transdifferentiation, experimental models 2: 142—143 2:
Transdifferentiation, future prospects 2: 150
Transdifferentiation, hematopoietic stem cells 2: 341—342 2: 2:
Transdifferentiation, liver to pancreas 2: 140—141
Transdifferentiation, master switch gene in 2: 150
Transdifferentiation, mesenchymal stem cells 2: 437
Transdifferentiation, metaplasia and 2: 139
Transdifferentiation, neural crest cells 1: 224—225
Transdifferentiation, pancreas to liver 2: 139—140
Transdifferentiation, potential CNS therapy 2: 696—697
Transdifferentiation, retinal pigmented epithelium 2: 704
Transdifferentiation, somatic cell potential 2: 147—148
Transdifferentiation, vs. cell fusion 2: 16 2: 2: 2: 2: 2:
Transfection 1: 724
Transfection by electroporation 1: 544
Transfection by viral infection 1: 544 2:
Transfection for clonal analysis 2: 652 2: 2: 2:
Transfection of ES cells by lentiviral vectors 1: 557—562
Transfection, advantages 1: 543—544
Transfection, mutagenesis risk 2: 657—658
Transfection, reagents 1: 544
Transfection, selection marker 1: 544
Transforming growth factor-alpha 1: 151
Transforming growth factor-alpha in hepatic stem cell activation 2: 506
Transforming growth factor-alpha in olfactory neurogenesis 2: 240
Transforming growth factor-beta in hematopoietic development 2: 390—391
Transforming growth factor-beta in hematopoietic stem cell cycle 2: 77 2: 2: 2:
Transforming growth factor-beta in hepatic stem cell activation 2: 506
Transforming growth factor-beta in neural crest cell development 2: 227—228
Transforming growth factor-beta in neurogenesis 1: 206 1:
Transforming growth factor-beta in olfactory progenitor differentiation 2: 240
Transforming growth factor-beta in spermatogonial stem cell culturing 1: 180
Transforming growth factor-beta in stem cell expansion 2: 74 (see also “Bone morphogenic protein”)
Transforming growth factor-beta, cyclin-dependent kinases and 2: 77 2:
Transforming growth factor-beta, knockouts 2: 118—119
Transgenic animals, lineage marking 1: 576 1:
Transgenic animals, phenotype variation in 1: 589—597
Transit cells 2: 3 2:
Transplantation medicine, alloantigenic matching 1: 668—669
Transplantation medicine, allogeneic transplants 2: 685 2:
Transplantation medicine, applications of genetic manipulation 1: 543 1:
Transplantation medicine, autologous human ES cell lines 1: 669—670
Transplantation medicine, autologous transplant 2: 685
Transplantation medicine, bone grafts 2: 772—773
Transplantation medicine, cartilage implants 2: 773—775
Transplantation medicine, cell delivery vehicles 2: 566
Transplantation medicine, diabetes treatment 1: 723
Transplantation medicine, ES cell-derived neural cells 1: 706—710
Transplantation medicine, ES-derived hepatocytes 1: 366 1:
Transplantation medicine, ethical issues in human cloning 1: 761—762
Transplantation medicine, heart disease treatment 1: 713—714 1: 1:
Transplantation medicine, hematopoietic progenitor cell clinical trials 2: 619—622 2:
Transplantation medicine, hematopoietic stem cells 2: 685—689
Transplantation medicine, human ES cell immunogenicity and 1: 663—671
Transplantation medicine, immune system challenges 1: 675
Transplantation medicine, immune-privileged graft sites 1: 668
Transplantation medicine, induction of immune tolerance in 1: 675 1:
Transplantation medicine, kidney interventions 2: 475—477
Transplantation medicine, ligament and tendon repair 2: 775—777
Transplantation medicine, liver therapies 1: 359—360 2:
Transplantation medicine, lung transplantation 1: 385—386
Transplantation medicine, meniscus repair 2: 775
Transplantation medicine, muscular dystrophy treatments 2: 721—722
Transplantation medicine, neural precursor cells 1: 513 1: 2:
Transplantation medicine, pathways of rejection 1: 664—668
Transplantation medicine, purity of stem cell populations for 2: 24
Transplantation medicine, regulatory controls 1: 775—785
Transplantation medicine, skeletal stem cells 2: 419
Transplantation medicine, skin grafts 1: 732—733
Transplantation medicine, skin grafts, cultured epidermal autografts 2: 247—248 2:
Transplantation medicine, solid tumor treatment 2: 739—742
Transplantation medicine, stem cell definition 2: 83
Transplantation medicine, strategies for minimizing rejection 1: 668—671
Transplantation medicine, supply of donor organs 1: 737
Transplantation medicine, syngeneic transplant 2: 685
Transplantation medicine, thymus epithelial cell preparation 2: 557—558
Transplantation medicine, tissue engineering applications 1: 737
Transplantation medicine, universal donor 1: 670—671
Transplantation medicine, use of common myeloid progenitors 2: 368—369
Transplantation medicine, use of conditional suicide genes in grafts 1: 543 1: 1:
Transplantation medicine, use of cord blood 2: 181—182
Transplantation medicine, use of cord blood, potential problems in 2: 182—185
Transplantation medicine, use of homologous recombination 1: 551 1:
Traps, gene 1: 547 1: 1:
Trithorax group activation 1: 67 1: 1: 1:
Trophectoderm 1: 27 1:
Trophectoderm in trophoblast development 1: 193—196
Trophectoderm, differentiation 1: 151 1:
Trophectoderm, epigenetic reprogramming 1: 660
Trophectoderm, formation 1: 129 1: 1: 1:
Trophectoderm, function 1: 273
Trophectoderm, implantation 1: 149 1:
Trophectoderm, mural 1: 193
Trophectoderm, polar 1: 129 1:
Trophoblast cells 1: 150
Trophoblast cells, function 1: 193
Trophoblast cells, giant cells 1: 193 1: 1:
Trophoblast stem cells 1: 91
Trophoblast stem cells for trophoblast modeling 1: 198—200
Trophoblast stem cells in placental development 1: 95—96
Trophoblast stem cells in X-chromosome inactivation 1: 200
Trophoblast stem cells, chimaeric capacity 1: 198
Trophoblast stem cells, derivation 1: 196 1:
Trophoblast stem cells, development 1: 193—197
Trophoblast stem cells, differentiation 1: 96
Trophoblast stem cells, hypoxic regulation 1: 96
Trophoblast stem cells, isolation and maintenance 1: 479—481
Trophoblast stem cells, oxygen-regulated gene expression 1: 91—92
Trophoblast stem cells, research utility 1: 193
Trypsinization of human ES cell cultures 1: 442—446 1: 1: 1:
Tumor necrosis factor 2: 504
Tumors, angiogenesis 2: 378
Tumors, gastrointestinal 1: 371 2: 2:
Tumors, hematopoietic stem cell therapy 2: 739—742
Tumors, in vivo fusion 2: 154 (see also “Cancer”)
Tumors, leukemogenesis 2: 315—316
Tumors, multipotent adult progenitor cell-induced 2: 294
Tyrosine hydroxylase in dopamine neuron differentition 1: 241—242
| Ulcers, skin 1: 731
Ulcers, skin, causes 1: 731
Ulcers, skin, cost of care 1: 731
Ulcers, skin, therapy 1: 734
Umbilical cord blood 2: 181—185
Umbilical cord blood, common lymphoid progenitors in 2: 350
Umbilical cord blood, cryopreservation 2: 182
Umbilical cord blood, engraftment capacity 2: 182
Umbilical cord blood, government regulation of stem cell products 2: 805
Umbilical cord blood, growth factor response 2: 181—182
Umbilical cord blood, Hoechst staining 2: 26
Umbilical cord blood, transplantation 2: 181
Umbilical cord blood, transplantation, potential problems 2: 182—185
Universal donor 1: 670—671
Upd signaling ligand 1: 174—175
Urogenital ridge 1: 345
Urothelial cells 2: 565
Uterine implantation 1: 149—152 1:
Uterine implantation, anatomy 1: 274f
Uterine implantation, postimplantation development 1: 195f
Uterine implantation, trophoblast function 1: 193
UTF genes 1: 36—37
Utrophin 2: 721
Vascular endothelial growth factor 1: 92 1:
Vascular endothelial growth factor in adult neovascularization 2: 461
Vascular endothelial growth factor in bone tissue engineering 2: 773
Vascular endothelial growth factor in ES cell differentiation 1: 317 1: 1: 1:
Vascular endothelial growth factor in hemangioblast development 1: 94
Vascular endothelial growth factor in hematopoiesis 2: 378 2:
Vascular endothelial growth factor in hematopoietic development 1: 94—95 2:
Vascular endothelial growth factor in lymphangiogenesis 2: 466—467
Vascular endothelial growth factor in proangiogenic stem cell recruitment 2: 377 2: 2: 2:
Vascular endothelial growth factor in vascular system development 2: 456—459
Vascular endothelial growth factor in yolk sac hematopoietic development 2: 160—161
Vascular endothelial growth factor, angiogenic action 2: 378 2:
Vascular endothelial growth factor, clinical potential 2: 383
Vascular endothelial growth factor, function 2: 773
Vascular stem-progenitor cells 2: 455
Vasculogenesis 1: 525 2: 2:
Vasculogenesis in myocardial regeneration 2: 450
Vasculogenesis in zebra fish 2: 677—678
Vasculogenesis, arteriovenous differentiation 2: 455 2:
Vasculogenesis, blood vessel patterning 2: 459
Vasculogenesis, bone development 2: 415 2:
Vasculogenesis, current status of experimental systems 1: 317
Vasculogenesis, embryonic formation, cellular mechanisms in 2: 455—456
Vasculogenesis, embryonic formation, molecular basis 2: 456—459
Vasculogenesis, embryonic kidney development 1: 342
Vasculogenesis, endothelial-hematopoietic cell relationship in 1: 323
Vasculogenesis, endothelial-smooth muscle cell relationship in 1: 323—324
Vasculogenesis, ES cell differentiation culture for 1: 317—321
Vasculogenesis, gonad development 1: 347—348 1: 1:
Vasculogenesis, hematopoietic emergence 1: 525—526
Vasculogenesis, lung development 1: 383—384
Vasculogenesis, lymphangiogenesis and 2: 467
Vasculogenesis, mammalian 1: 525—526
Vasculogenesis, mesenchymal stem cells in 2: 305
Vasculogenesis, progenitor cells 1: 323—327
Vasculogenesis, skin healing 1: 734—735
Vasculogenesis, thymus and parathyroid development 1: 395—396
Vasculogenesis, vascular regeneration in adult 2: 462—465
Vasculogenesis, yolk sac hematopoietic development 2: 161
Very late antigen—4 2: 597—598 2:
Viral gene delivery for genetic manipulation 1: 544 1:
Viral gene delivery for genetic manipulation for clonal analysis 2: 652 2: 2:
Viral gene delivery for genetic manipulation, advantages 1: 557
Viral gene delivery for genetic manipulation, genetic manipulation techniques 2: 792
Viral gene delivery for genetic manipulation, lentiviral vectors 1: 557—562
Viral gene delivery for genetic manipulation, retrovirus-based 1: 557—558
Viral gene delivery for genetic manipulation, vector design 1: 557—559
Viral infection, cell fusion in 2: 153
Vision problems, recovery after retinal regeneration 2: 706
Vision problems, therapeutic interventions 1: 253 1:
Vomeronasal organ 2: 233 2: 2:
WiCell 1: 795—797
Wilcoxon rank sum test 2: 646
Wilms tumor suppresser gene 1: 340 1:
Wisconsin Alumni Research Foundation 1: 793 1:
Wnt 2: 804
Wnt in cardiomyogenesis 1: 307
Wnt in central nervous system development 2: 192
Wnt in gastrointestinal development 1: 362—363
Wnt in gonad development 1: 350 1:
Wnt in hair follicle fate signaling 2: 65—66
Wnt in hematopoietic stem cell self-renewal 2: 28 2: 2:
Wnt in intestinal cell fate signaling 2: 68
Wnt in intestinal stem cell regulation 2: 532—533 2:
Wnt in neural crest cell development 2: 207
Wnt in neurogenesis 1: 206 1: 1:
Wnt in skin development 2: 262—264
Wnt in stem cell regulation 2: 552—553
Wnt, comparison of stem cell pathways 2: 32—33
Working cell bank 2: 808 2:
Wound healing therapies 1: 734—735 2:
X-chromosome inactivation 1: 63 1: 1: 1:
X-chromosome inactivation for clonal analysis 2: 654—656
X-chromosome inactivation in primate ES cells 1: 421
X-chromosome inactivation in thymus epithelial cell development 2: 561
X-chromosome inactivation, histone deacetylation and 2: 106—107
X-chromosome inactivation, purpose 2: 106
X-chromosome inactivation, reactivation 1: 189—190
X-chromosome inactivation, trophoblast stem cells in 1: 200
Xenopus 1: 483—491 1: 2: 2: 2: 2:
Xenotransplantation 2: 597 2: 2:
Xenotransplantation, definition 1: 780
Xenotransplantation, government regulation of 2: 806 2:
Xenotransplantation, safe practice 1: 780—781
Y-chromosome hybridization 2: 15
Yolk sac 1: 149 1:
Yolk sac in thymus development 2: 167—168
Yolk sac, erythropoiesis in 2: 161
Yolk sac, hematopoietic development 1: 282 2: 2: 2:
Yolk sac, hematopoietic progenitor cells from 1: 279 1:
Yolk sac, macrophage development in 2: 162
Yolk sac, mesoderm development 1: 273 1:
Yolk sac, vascular development 1: 323
Zebra fish 2: 389 2: 2:
Zebra fish ES cells, advantages 1: 493
Zebra fish ES cells, derivation 1: 493—495 1:
Zebra fish ES cells, germ-line chimera production 1: 493 1: 1:
Zebra fish ES cells, injection into host embryos 1: 496—497
Zebra fish ES cells, insertion of vector DNA by homologous recombination 1: 497—498 1:
Zebra fish ES cells, limitations 1: 493
Zebra fish, blood formation in 2: 677—678
Zebra fish, blood mutants 2: 679—680
Zebra fish, cell sorting and transplantation in 2: 680
Zebra fish, disease models 2: 681
Zebra fish, embryonic attributes 2: 677
Zebra fish, future research 2: 681—682
Zebra fish, genetic screens 2: 678—679
Zebra fish, mesenchymal cells, dental 2: 285
Zebra fish, morphology 2: 677
Zebra fish, research utility 2: 677
Zicl gene 2: 199
Zone of polarizing activity 1: 287
Zygotic genome activation 1: 66—67
|
|
|
| Ðåêëàìà |
|
|
|
|
|
|
|
|
Î ïðîåêòå